J&J, Pharma Mar Agree to End Patent Suits on Two Yondelis Copies

Johnson & Johnson’s Janssen unit and its partner Pharma Mar SA told two federal courts they’ve reached deals with drugmakers to end lawsuits over proposed copies of J&J’s cancer drug Yondelis.

Medchemexpress LLC conceded that US Patent Nos. 8,895,557 and 7,420,051 are valid and enforceable, according to a proposed consent judgment attached to a letter sent Tuesday to the US District Court for the District of New Jersey. Janssen and Pharma Mar’s letter to Judge Madeline Cox Arleo said “the parties have reached an amicable resolution of this matter.”

The deal would dismiss all claims with prejudice and bar the ...